Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up
Top Cited Papers
- 1 June 2012
- journal article
- research article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 71 (6) , 955-960
Abstract
Introduction The previously reported randomised controlled trial of a consensus regimen of pulse cyclophosphamide suggested that it was as effective as a daily oral (DO) cyclophosphamide for remission induction of antineutrophil cytoplasm autoantibodies-associated systemic vasculitis when both were combined with the same glucocorticoid protocol (CYCLOPS study (Randomised trial of daily oral versus pulse Cyclophosphamide as therapy for ANCA-associated Systemic Vasculitis published de groot K, harper L et al Ann Int Med 2009)). The study had limited power to detect a difference in relapse. This study describes the long-term outcomes of patients in the CYCLOPS study. Methods Long-term outcomes were ascertained retrospectively from 148 patients previously recruited to the CYCLOPS Trial. Data on survival, relapse, immunosuppressive treatment, cancer incidence, bone fractures, thromboembolic disease and cardiovascular morbidity were collected from physician records retrospectively. All patients were analysed according to the group to which they were randomised. Results Median duration of follow-up was 4.3 years (IQR, 2.95–5.44 years). There was no difference in survival between the two limbs (p=0.92). Fifteen (20.8%) DO and 30 (39.5%) pulse patients had at least one relapse. The risk of relapse was significantly lower in the DO limb than the pulse limb (HR=0.50, 95% CI 0.26 to 0.93; p=0.029). Despite the increased risk of relapse in pulse-treated patients, there was no difference in renal function at study end (p=0.82). There were no differences in adverse events between the treatment limbs. Discussion Pulse cyclophosphamide is associated with a higher relapse risk than DO cyclophosphamide. However, this is not associated with increased mortality or long-term morbidity. Although the study was retrospective, data was returned in 90% of patients from the original trial.Keywords
This publication has 19 references indexed in Scilit:
- Granulomatosis with polyangiitis (Wegener's): An alternative name for Wegener's granulomatosisAnnals of the Rheumatic Diseases, 2011
- Long-term patient survival in ANCA-associated vasculitisAnnals of the Rheumatic Diseases, 2011
- Selective Depletion of CD4+CD25+Foxp3+ Regulatory T Cells by Low-Dose Cyclophosphamide Is Explained by Reduced Intracellular ATP LevelsCancer Research, 2010
- Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic Antibody—Associated VasculitisAnnals of Internal Medicine, 2009
- EULAR recommendations for the management of primary small and medium vessel vasculitisAnnals of the Rheumatic Diseases, 2009
- Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task forceAnnals of the Rheumatic Diseases, 2008
- Histological and clinical predictors of early and late renal outcome in ANCA-associated vasculitisNephrology Dialysis Transplantation, 2004
- Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: A prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty‐five patientsArthritis Care & Research, 2003
- The value of pulse cyclophosphamide in ANCA‐associated vasculitis: meta‐analysis and critical reviewNephrology Dialysis Transplantation, 2001
- Wegener Granulomatosis: An Analysis of 158 PatientsAnnals of Internal Medicine, 1992